Physician
Dermatology
Dr. David J. Kerr, MD
|
|
Give Review
David Kerr is an expert in the field of Dermatology. He graduated from University of Michigan Medical School. He has 2 awards "Fellow (FAAD)" and "Whos Who in Medicine and Healthcare". David J. Kerr is also published. He has 101 publications published. The lastest publication: "Refinement of the associations between risk of colorectal cancer and polymorphisms on chromosomes 1q41 and 12q13.13.'
Publications
- TERC polymorphisms are associated both with susceptibility to colorectal Cancer and with longer telomeres.
- Refinement of the associations between risk of colorectal Cancer and polymorphisms on chromosomes 1q41 and 12q13.13.
- Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Ca...
- Challenges of Cancer control in developing countries: current status and future perspective.
- A two-phase case-control study for colorectal Cancer genetic susceptibility: candidate genes from chromosomal regions 9q22 and 3q22.
- Delivering affordable Cancer care in high-income countries.
- Predictive biomarkers: a paradigm shift towards personalized Cancer medicine.
- Fine-mapping of colorectal Cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest funct...
- Documenting the Natural History of Patients With Resected Stage II AdenoCarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observ...
- The emergence of 'omics for the management of colorectal Cancer.
- The diagnosis and management of gastric Cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.
- Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal Cancer.
- Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor...
- Passing judgement on Lansley''s vision.
- Targeted therapies: bevacizumab--has it reached its final resting place?
- Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal Cancer.
- KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal Cancer.
- It''s life but not as we know it.
- Gene expression signature to improve prognosis prediction of stage II and III colorectal Cancer.
- Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal Cancer patients.
- Sensor-augmented insulin-pump therapy in type 1 diabetes.
- Multicenter user evaluation of ACCU-CHEK® Combo, an integrated system for continuous subcutaneous insulin infusion.
- Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal Cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.
- Roles of tetrahydrobiopterin in promoting tumor angiogenesis.
- Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal Cancer: final results of the VICTOR trial.
- Can we treat Cancer for a dollar a day? Guidelines for low-income countries.
- Quinone oxidoreductase-2-mediated prodrug Cancer therapy.
- Defective mismatch repair in colon Cancer: a prognostic or predictive biomarker?
- Pascal's wager: combining continuous glucose monitoring and continuous subcutaneous insulin infusion.
- Gene profiling in early stage disease.
- Comprehensive assessment of variation at the transforming growth factor beta type 1 receptor locus and colorectal Cancer predisposition.
- International network of Cancer genome projects.
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
- Regional hepatic chemotherapies in the treatment of colorectal Cancer metastases to the liver.
- Health policy just got personal.
- Novel treatments for hepatoCellular cancer.
- What is the role and impact of molecular markers on treatment decisions for colorectal Cancer in the adjuvant setting?
- British lessons on health care reform.
- Targeted therapies: Cetuximab plus chemotherapy in patients with advanced NSCLC.
- Randomized control trial investigating the influence of coffee on heart rate variability in patients with ST-segment elevation myocardial infarction.
- Genetic prognostic and predictive markers in colorectal Cancer.
- Open access chemical and clinical probes to support drug discovery.
- The management of hepatoCellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.
- Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal Cancer.
- Common variation at the adiponectin locus is not associated with colorectal Cancer risk in the UK.
- Glucose intolerance during adjuvant chemotherapy for breast Cancer.
- Warfarin thromboprophylaxis in Cancer patients with central venous catheters (WARP): an open-label randomised trial.
- Evolution of nonsurgical therapy for colorectal Cancer.
- Malignant peritoneal mesothelioma. Is there a new treatment?
- Capecitabine: have we got the dose right?
- A phase II study of adoptive immunotherapy using dendritic Cells pulsed with tumor lysate in patients with hepatoCellular carcinoma.
- Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal Cancer.
- Refinement of the basis and impact of common 11q23.1 variation to the risk of developing colorectal Cancer.
- Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study.
- Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (...
- What is the role and impact of molecular markers on treatment decisions in the adjuvant setting of colorectal Cancer?
- The diagnosis and management of rectal Cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.
- A genome-wide association study identifies colorectal Cancer susceptibility loci on chromosomes 10p14 and 8q23.3.
- The challenge of Cancer control in Africa.
- Metastatic colorectal Cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment.
- Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis.
- Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomised controlled trial.
- Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal Cancer risk.
- Adjuvant chemotherapy versus observation in patients with colorectal Cancer: a randomised study.
- A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
- End points for colon Cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials ...
- Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal Cancer.
- The management of pancreatic Cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.
- Bacteriophage biopanning in human tumour biopsies to identify Cancer-specific targeting ligands.
- Chemotherapy for colorectal Cancer in the metastatic and adjuvant setting: past, present and future.
- Identification of an oligopeptide binding to hepatoCellular carcinoma.
- Standard operating procedure for the collection of fresh frozen tissue samples.
- Virtual microscopy in virtual tumor banking.
- TuBaFrost 6: virtual microscopy in virtual tumour banking.
- TuBaFrost 5: multifunctional central database application for a European tumor bank.
- Predictors of ambulance use in patients with acute myocardial infarction in Australia.
- TuBaFrost 1: Uniting local frozen tumour banks into a European network: an overview.
- TuBaFrost 4: access rules and incentives for a European tumour bank.
- TuBaFrost 2: Standardising tissue collection and quality control procedures for a European virtual frozen tissue bank network.
- Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?
- Functional categories of TP53 mutation in colorectal Cancer: results of an International Collaborative Study.
- Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
- TuBaFrost: European virtual tumor tissue banking.
- Disease-free survival versus overall survival as a primary end point for adjuvant colon Cancer studies: individual patient data from 20,898 patients on 18 randomized t...
- Single-dose clinical pharmacokinetic studies of gefitinib.
- The TP53 colorectal Cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, ...
- Overweight children and adolescents.
- Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus Cancer gene therapy.
- Bevacizumab--current status and future directions.
- A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal Cancer.
- Adjuvant chemotherapy for stage II colorectal Cancer: the time is right!
- Fluorescence studies of the intra-Cellular distribution of zinc bis(thiosemicarbazone) complexes in human cancer Cells.
- Signal transduction blockade and Cancer: combination therapy or multi-targeted inhibitors?
- Targeting angiogenesis in Cancer: clinical development of bevacizumab.
- Nitroreductase: a prodrug-activating enzyme for Cancer gene therapy.
- Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours?
- Two errors.
- Can we individualize chemotherapy for colorectal Cancer?
- Hepatic arterial chemotherapy for colorectal Cancer liver metastases: a review of advances in 2003.
- Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
Schools
University Of Michigan Medical School
St Joseph Hospital
Oregon Health and Science University
Procedures Preformed
- Destruction of Benign Skin Lesion
- Destruction of Malignant Skin Lesion
- Excision of Malignant Skin Lesion
Conditions Treated
- Acne
- Actinic Keratosis
- Basal Cell Carcinoma
- Dermatitis
- View All
Doctors Specialties
- Dermatology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Pathway X Bronze Direct CACA IN HIX
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Cofinity PPO
- Coventry Health Care of Nebraska PPO
- First Health (Coventry Health Care) PPO
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Fellow (FAAD)
- Whos Who in Medicine and Healthcare
Education
-
Oregon Health & Science University -
Exempla St Joseph Hospital -
University of Michigan Medical School
Drug Facts
| NPI NUMBER | 1538164058 | |
| NPPES Provider LastName | KERR | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 802203917 | |
| NPPES Provider State | CO | |
| Specialty Description | Dermatology | |
| Total Claim Count | 398.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1538164058 |
| Last Name Of The Provider | KERR |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. John E. Blomstedt III, DO
 This Doctor is OpenDoctor Recommended.
|